New trial aims to boost survival in kids with rare lymphoma

NCT ID NCT05681260

First seen Mar 22, 2026 · Last updated May 13, 2026 · Updated 8 times

Summary

This study tests which of two chemotherapy methods works better for children newly diagnosed with T-cell lymphoblastic lymphoma, a rare cancer. About 200 children will receive either high-dose methotrexate or a different escalating dose, both combined with standard drugs. The goal is to improve the chance of staying cancer-free and to learn more about how to interpret PET scans and treat those who don't respond early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T CELL LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Children's Medical Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200127, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • West China Second University Hospital

    NOT_YET_RECRUITING

    Chengdu, China

    Contact

Conditions

Explore the condition pages connected to this study.